These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

32 related articles for article (PubMed ID: 24308040)

  • 1. Piperacillin/tazobactam resistance in a clinical isolate of Escherichia coli due to IS26-mediated amplification of bla
    Hubbard ATM; Mason J; Roberts P; Parry CM; Corless C; van Aartsen J; Howard A; Bulgasim I; Fraser AJ; Adams ER; Roberts AP; Edwards T
    Nat Commun; 2020 Oct; 11(1):4915. PubMed ID: 33004811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Win Ratio Analyses of Piperacillin-Tazobactam Versus Meropenem for Ceftriaxone-Nonsusceptible Escherichia coli or Klebsiella pneumoniae Bloodstream Infections: Post Hoc Insights From the MERINO Trial.
    Hardy M; Harris PNA; Paterson DL; Chatfield MD; Mo Y;
    Clin Infect Dis; 2024 Jun; 78(6):1482-1489. PubMed ID: 38306577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capnocytophaga sputigena bacteremia in a patient with chronic lymphocytic leukemia.
    Kim JA; Hong SK; Kim EC
    Ann Lab Med; 2014 Jul; 34(4):325-7. PubMed ID: 24982840
    [No Abstract]   [Full Text] [Related]  

  • 4. Letter responding to performance of updated
    Patel JB; Duncan E; Cullen S
    J Clin Microbiol; 2023 Nov; 61(11):e0049723. PubMed ID: 37823655
    [No Abstract]   [Full Text] [Related]  

  • 5. Photo Quiz: A 44-Year-Old Kidney Transplant Patient with Pneumonia.
    Compain F; Rossi B; Richaud C; Guerot E; Rostane H; Jarraud S; Podglajen I
    J Clin Microbiol; 2017 Jan; 55(1):1-2. PubMed ID: 28031443
    [No Abstract]   [Full Text] [Related]  

  • 6. Nosocomial spontaneous bacterial peritonitis antibiotic treatment in the era of multi-drug resistance pathogens: A systematic review.
    Fiore M; Maraolo AE; Gentile I; Borgia G; Leone S; Sansone P; Passavanti MB; Aurilio C; Pace MC
    World J Gastroenterol; 2017 Jul; 23(25):4654-4660. PubMed ID: 28740354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparable outcomes for β-lactam/β-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae.
    Harris PN; Yin M; Jureen R; Chew J; Ali J; Paynter S; Paterson DL; Tambyah PA
    Antimicrob Resist Infect Control; 2015; 4():14. PubMed ID: 25932324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Escherichia coli sequence type 131: epidemiology and challenges in treatment.
    Qureshi ZA; Doi Y
    Expert Rev Anti Infect Ther; 2014 May; 12(5):597-609. PubMed ID: 24694052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In the literature. Piperacillin-tazobactam and extended-spectrum β-lactamase--producing Escherichia coli.
    Clin Infect Dis; 2013 Nov; 57(10):iii-iv. PubMed ID: 24308040
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
    López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
    Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-tazobactam combinations.
    Liu Q; Rand K; Derendorf H
    Int J Antimicrob Agents; 2004 May; 23(5):494-7. PubMed ID: 15120729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam.
    Peterson LR
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():181-4. PubMed ID: 18154544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of the increased use of piperacillin/tazobactam on the selection of antibiotic resistance among invasive Escherichia coli and Klebsiella pneumoniae isolates.
    Lee J; Oh CE; Choi EH; Lee HJ
    Int J Infect Dis; 2013 Aug; 17(8):e638-43. PubMed ID: 23523562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro efficacy of ceftriaxone/sulbactam against Escherichia coli isolates producing CTX-M-15 extended-spectrum beta-lactamase.
    Shahid M; Singhai M; Malik A; Shukla I; Khan HM; Shujatullah F; Tahira F
    J Antimicrob Chemother; 2007 Jul; 60(1):187-8. PubMed ID: 17491002
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.